News Network

  

AAN 2020: Multiple Sclerosis Treatment Considerations


Jiwon Oh, MD, PhD, comments on potential risk factors that may increase a multiple sclerosis patient’s risk for acquiring coronavirus or complications of COVID-19 and discusses what is being done in clinical practice to reduce a patient’s risk during the pandemic.

Jiwon Oh, MD, PhD, discusses recent recommendations by the National Multiple Sclerosis Society on the use of disease-modifying therapies to treat MS during the coronavirus pandemic.

Implications for treating patients with multiple sclerosis with cladribine tablets based on long-term efficacy data revealed at the 2020 AAN Annual Meeting.

Jiwon Oh, MD, PhD, reflects on some of the most interesting abstract data for multiple sclerosis from the 2020 AAN Annual Meeting.

Considerations for appropriately treating patients with multiple sclerosis with disease-modifying therapies during the COVID-19 pandemic.
SAP Partner Banner